First-line treatment of chronic myeloid leukaemia

Abstract

Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.

Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies

“…Many studies have already been conducted on the combination of TKIs with conventional therapies, including chemotherapy, radiation therapy, interferon therapy, etc. A study showed that combination of standard-dose imatinib and IF-therapy yielded better results than standard-dose or high-dose imatinib alone, as well as standard-dose imatinib combined with chemotherapy [21,163]. Icotinib, an EGFR-TKI is proved to improve radiosensitivity in lung cancer in vitro and in vivo, thus possibly allowing better radiotherapy effects [164].…”